Papers about tirzepatide

Every paper here, unless its row says otherwiseIndexed under tirzepatide in PubMed's chemical list; returned by a PubMed search for tirzepatide

• Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study.

  Obesity surgery2024PMID 38430320Indexed under tirzepatide in PubMed's chemical list

• Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety.

  Obesity reviews2024PMID 38463003Indexed under tirzepatide in PubMed's chemical list

• Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes.

  Diabetes technology & therapeutics2024PMID 38512447

• Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials.

  Diabetes care2024PMID 38530948

• Evidence that tirzepatide protects against diabetes-related cardiac damages.

  Cardiovascular diabetology2024PMID 38555463Also tests tirzepatide

• Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.

  Diabetologia2024PMID 38613667Indexed under tirzepatide in PubMed's chemical list

• Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.

  Diabetes care2024PMID 38639997

• Tirzepatide and exercise training in obesity.

  Clinical hemorheology and microcirculation2024PMID 38640145Returned by a PubMed search for tirzepatide

• Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single-Centre Retrospective Study.

  Endocrinology, diabetes & metabolism2024PMID 38718272Returned by a PubMed search for tirzepatide

• Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment.

  Endocrine practice2024PMID 38723893

• Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.

  Alimentary pharmacology & therapeutics2024PMID 38768298Returned by a PubMed search for tirzepatide

• Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.

  Diabetes research and clinical practice2024PMID 38777128Indexed under tirzepatide in PubMed's chemical list

• Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population.

  Diabetes, obesity & metabolism2024PMID 38783825

• Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test.

  The Journal of clinical endocrinology and metabolism2024PMID 38795393Indexed under tirzepatide in PubMed's chemical list

• Characterization of tirzepatide-treated patients achieving different glycemic control levels in SURPASS-AP-Combo.

  Obesity (Silver Spring, Md.)2024PMID 38803303

• Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.

  JAMA2024PMID 38819983

• Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.

  Endocrine2024PMID 38850440Also tests tirzepatide

• Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.

  The New England journal of medicine2024PMID 38856224

• Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.

  The New England journal of medicine2024PMID 38912654

• Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.

  Diabetes, obesity & metabolism2024PMID 38923379Also indexed under tirzepatide as a PubMed major topic

• Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.

  Diabetes research and clinical practice2024PMID 38925294Returned by a PubMed search for tirzepatide

• Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.

  JAMA internal medicine2024PMID 38976257Indexed under tirzepatide in PubMed

• Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials.

  International journal of clinical pharmacy2024PMID 39037553Returned by a PubMed search for tirzepatide

• Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.

  Heart (British Cardiac Society)2024PMID 39084707Returned by a PubMed search for tirzepatide

• Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes.

  JAMA network open2024PMID 39133485

• Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the tirzepatide treatment on coronary atherosclerosis progression: The (T-Plaque) randomized-controlled trial design.

  American heart journal2024PMID 39187147Returned by a PubMed search for tirzepatide

• Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J-mono and J-combo studies.

  Diabetes, obesity & metabolism2024PMID 39192522

• Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials.

  International journal of obesity (2005)2024PMID 39210008

• Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism2024PMID 39248221

• Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis.

  BMC endocrine disorders2024PMID 39719583

• Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).

  Diabetes, obesity & metabolism2023PMID 36184780

• Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.

  Diabetes, obesity & metabolism2023PMID 36514843

• Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.

  Diabetes, obesity & metabolism2023PMID 36700380

• Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.

  Diabetes care2023PMID 36857477

• A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?

  Frontiers in endocrinology2023PMID 37051199

• Weight loss efficiency and safety of tirzepatide: A Systematic review.

  PloS one2023PMID 37141329

• Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial.

  Nature medicine2023PMID 37231074

• Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.

  International journal of obesity (2005)2023PMID 37253796

• A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes.

  Advances in therapy2023PMID 37285081

• Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

  Lancet (London, England)2023PMID 37385275

• Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.

  Clinical therapeutics2023PMID 37455226

• Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.

  International journal of obesity (2005)2023PMID 37460681

• Is tirzepatide 15 mg the preferred treatment strategy for type 2 diabetes? A meta-analysis and trial-sequence-analysis.

  European review for medical and pharmacological sciences2023PMID 37606127

• The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials.

  Frontiers in endocrinology2023PMID 37621649

• Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials.

  Diabetes, obesity & metabolism2023PMID 37700437

• Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial.

  Diabetes, obesity & metabolism2023PMID 37700443

• Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.

  JAMA2023PMID 37786396

• Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.

  Nature medicine2023PMID 37840095

• Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: A meta-analysis and trials sequential analysis.

  Medicine2023PMID 37904345

• Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.

  Frontiers in endocrinology2023PMID 37908750